Search
News & Events
300th participant recruited to crucial respiratory research programA research program, which enables over 25 important respiratory research studies to be undertaken, celebrated the recruitment of its 300th participant on 14 December 2022.
News & Events
Research to help identify which children will develop asthma and to design more specific asthma treatments supported by Federal Government fundingResearch focussed on identifying which children will develop asthma, and developing more specific asthma treatments, has been supported by the National Health and Medical Research Council’s (NHMRC) Ideas Grants announced by the Federal Government on 14 December 2022.
News & Events
Community engagement vital in battle against antimicrobial resistance: Wal-yan Centre to establish reference groupThe Wal-yan Respiratory Research Centre is seeking expressions of interest from Western Australians to join an Antimicrobial Resistance (AMR) Community Reference Group, to provide vital community perspectives on the research activities into this global health concern.
News & Events
Research into innovative treatments for asthma and antibiotic-resistant infections fuelled by Stan Perron Charitable Foundation grantsNew funding from the Stan Perron Charitable Foundation will support research into innovative treatments for antibiotic-resistant infections and asthma in children, led by Wal-yan Respiratory Research Centre researchers.
We've compiled a number of helpful links to phage resources in Australia and beyond.
Bronchiectasis is a condition where the lungs become damaged and prone to infections.
The Australian Epithelial Research Program (WAERP) comprises of several parties, including our Chief Investigators, Compliance, Scientific and Clinical Teams, and our Student group.
The Scientific Advisory Committee's (SAC) role is to provide scientific direction and to ensure the objectives of WAERP are reflected in the research performed; SAC forms part of our governance structure.
Want to know how to be involved with WAERP? Or how long the project is running for? View our Frequently Asked Questions (FAQs) for answers to these questions and more.
Research
Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trialWe tested if disrupting iron utilisation by P. aeruginosa by adding the Tris-buffered chelating agent CaEDTA to nebulised tobramycin would enhance bacterial clearance and improve lung function in CF patients.